Genmab A/S (NASDAQ:GMAB) To See Near-Term Downside Pressure Despite Active Buyback

Genmab enters the coming weeks with defensive technicals and mixed operating fundamentals while corporate actions supply episodic support. The current valuation as determined by WMDST classifies the stock as under-valued.

Recent News

Feb. 17, 2026 — Genmab published its 2025 Annual Report, outlining corporate performance and strategic priorities for 2026.

Feb. 17, 2026 — The company initiated a DKK 725 million share buy-back program to repurchase up to 342,130 shares, reporting initial transactions under that program.

Genmab announced the convening of its Annual General Meeting for March 19, 2026.

Genmab closed a private offering of senior secured notes, increasing liquidity and senior secured financing capacity.

Technical Analysis

ADX reads 17.55, indicating a lack of a clear trend; directional indicators nevertheless skew bearish as DI+ decreased while DI- increased, implying sellers currently exert greater directional pressure and limiting upside conviction.

MACD stands at -0.26 and trends downward below its signal line (-0.13), showing bearish momentum and indicating short-term momentum remains negative versus prior signal levels.

MRO registers 18.41 with a peak-and-reversal pattern; because MRO sits positive, price sits above target and carries increased downside potential toward the target level, reinforcing bearish momentum signals from MACD and directional indicators.

RSI at 45.11 and decreasing signals mild downside bias without an oversold condition; the move below the neutral 50 midpoint aligns with weakening short-term internals rather than capitulation.

Price sits under the 20-day average ($27.57) and the 200-day average ($28.76), with the 12‑ and 26‑day EMAs declining; these placements, together with Ichimoku conversion/base levels above the close, position moving averages and indicators as resistance that must be overcome for a constructive recovery.

Bollinger band placement shows the close ($26.52) barely above the 1x lower band ($26.45), suggesting limited immediate downside buffer but confirming proximity to recent lower-range support levels; volume runs below 10‑ and 200‑day averages, reducing the conviction behind intraday moves and increasing sensitivity to news-driven spikes.

 


Fundamental Analysis

Operating performance shows positive operating margin of 22.97% and an EBIT margin of 9.36%, with EBIT of $99.0M and EBITDA of $120.0M. The EBIT margin sits above the industry peer mean (-0.883%) and above the industry peer median (0.2125%), indicating relative operating resilience versus peers, even as quarter-over-quarter and year-over-year margin deltas contracted.

Revenue totaled $1,058.0M with reported revenue growth of 3.52% on the primary metric but a year-over-year revenue change listed at -78.34%; sequential indicators show revenue weakened quarter-to-quarter. R&D investment remains sizable at $526.0M, supporting pipeline depth but pressuring operating leverage.

Earnings per share came in at $0.21 versus an estimate of $0.37, producing an EPS surprise of -43.24%, and trailing P/E at 150.69 contrasts with a forward P/E of 67.65. Price-to-book at 0.33 sits below the industry peer mean (5.19636) and median (6.16434), while PEG sits negative at -2.23 versus an industry peer mean around -1.08, reflecting a complex mix of elevated valuation multiples and negative growth signals.

Free cash flow shows strength in absolute terms ($288.0M) and a free cash flow yield of 14.78%, well above the industry peer mean (~0.16%), supporting balance sheet flexibility. Cash and short-term investments total $1.715B and cash plus equivalents provide a cash ratio of 1.20 and a current ratio of 2.02, underwriting near-term liquidity.

Leverage presents a counterpoint: total debt $5.426B, net debt $3.559B, and debt-to-EBITDA ~45.2 with interest coverage near 2.25, signaling elevated leverage relative to operating cash generation; the recent secured-note financing increases liquidity but maintains material leverage obligations.

WMDST values the stock as under-valued based on the firm’s cash generation, pipeline assets, and adjusted valuation framework; however, the company’s negative EPS surprise, elevated leverage metrics, and mixed growth signals temper margin of safety and argue for cautious interpretation of the valuation signal.

MOST-RECENT QUARTERLY REPORT
REPORT PERIOD ENDING: 2025-12-31
REPORT DATE: 2026-02-17
NEXT REPORT DATE: 2026-05-19
CASH FLOW  Begin Period Cash Flow 1.8 B
 Operating Cash Flow 301.0 M
 Capital Expenditures -13.00 M
 Change In Working Capital 253.0 M
 Dividends Paid
 Cash Flow Delta -46.00 M
 End Period Cash Flow 1.7 B
 
INCOME STATEMENT REVENUE
 Total Revenue 1.1 B
 Forward Revenue 226.4 M
COSTS
 Cost Of Revenue 81.0 M
 Depreciation 16.0 M
 Depreciation and Amortization 21.0 M
 Research and Development 526.0 M
 Total Operating Expenses 815.0 M
PROFITABILITY
 Gross Profit 977.0 M
 EBITDA 120.0 M
 EBIT 99.0 M
 Operating Income 243.0 M
 Interest Income 48.0 M
 Interest Expense 44.0 M
 Net Interest Income 4.0 M
 Income Before Tax 55.0 M
 Tax Provision 24.0 M
 Tax Rate 22.0 %
 Net Income 31.0 M
 Net Income From Continuing Operations 55.0 M
EARNINGS
 EPS Estimate 0.37
 EPS Actual 0.21
 EPS Difference -0.16
 EPS Surprise -43.243 %
 Forward EPS 0.43
 
BALANCE SHEET ASSETS
 Total Assets 12.9 B
 Intangible Assets 9.5 B
 Net Tangible Assets -3.63 B
 Total Current Assets 2.9 B
 Cash and Short-Term Investments 1.7 B
 Cash 1.7 B
 Net Receivables 1.1 B
 Inventory 18.0 M
 Long-Term Investments
LIABILITIES
 Accounts Payable
 Short-Term Debt 273.0 M
 Total Current Liabilities 1.4 B
 Net Debt 3.6 B
 Total Debt 5.4 B
 Total Liabilities 7.0 B
EQUITY
 Total Equity 5.8 B
 Retained Earnings 4.1 B
VALUATION & PER-SHARE METRICS EQUITY & PER-SHARE METRICS
 Book Value Per-Share 94.92
 Shares Outstanding 61.599 M
 Revenue Per-Share 17.18
VALUATION
 Market Capitalization 1.9 B
 Enterprise Value 5.7 B
 Enterprise Multiple 47.169
Enterprise Multiple QoQ -1653.704 %
Enterprise Multiple YoY -1049.503 %
Enterprise Multiple IPRWA high: 67.346
GMAB: 47.169
median: 44.062
mean: 12.25
low: -114.076
 EV/R 5.35
CAPITAL STRUCTURE
 Asset To Equity 2.202
 Asset To Liability 1.832
 Debt To Capital 0.481
 Debt To Assets 0.421
Debt To Assets QoQ 1983.539 %
Debt To Assets YoY 1776.67 %
Debt To Assets IPRWA high: 0.934
GMAB: 0.421
mean: 0.117
median: 0.005
low: 0.0
 Debt To Equity 0.928
Debt To Equity QoQ 3658.607 %
Debt To Equity YoY 3209.558 %
Debt To Equity IPRWA high: 1.519
GMAB: 0.928
mean: 0.142
median: 0.005
low: -0.893
PRICE-BASED VALUATION
 Price To Book (P/B) 0.333
Price To Book QoQ 10.066 %
Price To Book YoY 813.871 %
Price To Book IPRWA high: 19.432
median: 6.164
mean: 5.196
GMAB: 0.333
low: -10.511
 Price To Earnings (P/E) 150.686
Price To Earnings QoQ 246.178 %
Price To Earnings YoY 507.943 %
Price To Earnings IPRWA GMAB: 150.686
high: 75.085
mean: -0.822
median: -16.622
low: -119.903
 PE/G Ratio -2.226
 Price To Sales (P/S) 1.842
Price To Sales QoQ 8.093 %
Price To Sales YoY 786.446 %
Price To Sales IPRWA high: 773.807
mean: 48.9
median: 20.207
GMAB: 1.842
low: -75.758
FORWARD MULTIPLES
Forward P/E 67.651
Forward PE/G -0.999
Forward P/S 8.198
EFFICIENCY OPERATIONAL
 Operating Leverage -22.594
ASSET & SALES
 Asset Turnover Ratio 0.106
Asset Turnover Ratio QoQ -29.832 %
Asset Turnover Ratio YoY -29.432 %
Asset Turnover Ratio IPRWA high: 0.406
mean: 0.116
median: 0.109
GMAB: 0.106
low: -0.066
 Receivables Turnover 0.981
Receivables Turnover Ratio QoQ -1.946 %
Receivables Turnover Ratio YoY -1.809 %
Receivables Turnover Ratio IPRWA high: 7.397
mean: 1.448
median: 1.333
GMAB: 0.981
low: -1.505
 Inventory Turnover 5.062
Inventory Turnover Ratio QoQ 17.834 %
Inventory Turnover Ratio YoY -0.102 %
Inventory Turnover Ratio IPRWA GMAB: 5.062
high: 2.026
mean: 0.574
median: 0.471
low: 0.007
 Days Sales Outstanding (DSO) 93.061
CASH CYCLE
 Cash Conversion Cycle Days (CCC) 118.234
Cash Conversion Cycle Days QoQ 4.76 %
Cash Conversion Cycle Days YoY
Cash Conversion Cycle Days IPRWA high: 974.716
median: 189.511
mean: 189.033
GMAB: 118.234
low: -1689.26
CAPITAL DEPLOYMENT
 Cash Conversion Ratio 0.726
 CapEx To Revenue -0.012
 CapEx To Depreciation -0.812
 
CAPITAL, LIQUIDITY & COVERAGE CAPITAL STRUCTURE
 Total Capital 10.8 B
 Net Invested Capital 11.1 B
 Invested Capital 11.1 B
 Net Tangible Assets -3.63 B
 Net Working Capital 1.5 B
LIQUIDITY
 Cash Ratio 1.202
 Current Ratio 2.022
Current Ratio QoQ -66.493 %
Current Ratio YoY -61.473 %
Current Ratio IPRWA high: 27.397
mean: 3.74
median: 2.827
GMAB: 2.022
low: 0.027
 Quick Ratio 2.009
Quick Ratio QoQ -66.597 %
Quick Ratio YoY -61.628 %
Quick Ratio IPRWA high: 13.851
mean: 2.744
median: 2.452
GMAB: 2.009
low: 0.069
COVERAGE & LEVERAGE
 Debt To EBITDA 45.217
 Cost Of Debt 1.233 %
 Interest Coverage Ratio 2.25
Interest Coverage Ratio QoQ -98.608 %
Interest Coverage Ratio YoY -96.677 %
Interest Coverage Ratio IPRWA high: 671.002
mean: 40.359
median: 3.11
GMAB: 2.25
low: -1571.333
 Operating Cash Flow Ratio -0.013
TIMING / LIQUIDITY
 Days Payables Outstanding (DPO)
DIVIDENDS
 Dividend Coverage Ratio
 Dividend Payout Ratio
 Dividend Rate
 Dividend Yield
PERFORMANCE GROWTH
 Asset Growth Rate 83.35 %
 Revenue Growth 3.523 %
Revenue Growth QoQ -66.403 %
Revenue Growth YoY -78.339 %
Revenue Growth IPRWA high: 420.0 %
mean: 12.595 %
GMAB: 3.523 %
median: 3.463 %
low: -242.388 %
 Earnings Growth -67.692 %
Earnings Growth QoQ -432.312 %
Earnings Growth YoY -135.055 %
Earnings Growth IPRWA high: 204.0 %
median: -14.286 %
mean: -16.847 %
GMAB: -67.692 %
low: -237.5 %
MARGINS
 Gross Margin 92.344 %
Gross Margin QoQ -2.1 %
Gross Margin YoY -2.558 %
Gross Margin IPRWA high: 102.453 %
GMAB: 92.344 %
median: 78.702 %
mean: 78.511 %
low: -63.166 %
 EBIT Margin 9.357 %
EBIT Margin QoQ -80.283 %
EBIT Margin YoY -83.515 %
EBIT Margin IPRWA high: 3501.566 %
median: 21.25 %
GMAB: 9.357 %
mean: -88.314 %
low: -7602.597 %
 Return On Sales (ROS) 22.968 %
Return On Sales QoQ -48.86 %
Return On Sales YoY -59.536 %
Return On Sales IPRWA high: 1116.376 %
median: 27.297 %
GMAB: 22.968 %
mean: -98.626 %
low: -7602.597 %
CASH FLOW
 Free Cash Flow (FCF) 288.0 M
 Free Cash Flow Yield 14.775 %
Free Cash Flow Yield QoQ -51.802 %
Free Cash Flow Yield YoY -92.123 %
Free Cash Flow Yield IPRWA high: 21.452 %
GMAB: 14.775 %
median: 0.303 %
mean: 0.157 %
low: -51.848 %
 Free Cash Growth -46.067 %
Free Cash Growth QoQ -104.97 %
Free Cash Growth YoY -273.844 %
Free Cash Growth IPRWA high: 177.21 %
median: -24.526 %
mean: -32.837 %
GMAB: -46.067 %
low: -201.25 %
 Free Cash To Net Income 9.29
 Cash Flow Margin -1.701 %
 Cash Flow To Earnings -0.581
VALUE & RETURNS
 Economic Value Added 0.02
 Return On Assets (ROA) 0.312 %
Return On Assets QoQ -94.754 %
Return On Assets YoY -96.532 %
Return On Assets IPRWA high: 33.814 %
median: 1.099 %
GMAB: 0.312 %
mean: -2.706 %
low: -65.985 %
 Return On Capital Employed (ROCE) 0.865 %
 Return On Equity (ROE) 0.005
Return On Equity QoQ -92.399 %
Return On Equity YoY -94.942 %
Return On Equity IPRWA high: 0.809
median: 0.036
GMAB: 0.005
mean: 0.001
low: -1.16
 DuPont ROE 0.535 %
 Return On Invested Capital (ROIC) 0.694 %
Return On Invested Capital QoQ -90.108 %
Return On Invested Capital YoY -104.885 %
Return On Invested Capital IPRWA high: 50.944 %
median: 3.016 %
GMAB: 0.694 %
mean: -0.123 %
low: -58.737 %

Six-Week Outlook

Technicals project limited directional conviction: ADX indicates no strong trend while directional and momentum indicators lean bearish, and price remains below key moving averages. Corporate actions — a DKK 725 million buy-back and recent secured-note financing — provide episodic support and liquidity that could cap downside volatility around structural support levels, while the next scheduled report (May 19, 2026) represents a near-term catalyst for renewed volatility.

Expect the near-term price environment to remain range-bound with a modest downside bias until momentum indicators stabilize or material pipeline/operational news shifts investor calculus; lower average daily volume increases the odds that headlines will drive outsized intraday moves during this period.

About Genmab A/S

Genmab A/S (NASDAQ:GMAB) develops innovative antibody therapeutics targeting cancer and other serious diseases. Based in Copenhagen, Denmark, Genmab has introduced several significant therapies, including DARZALEX, a leading treatment for multiple myeloma, and teprotumumab for thyroid eye disease. The company’s pipeline includes advanced products like Amivantamab for gastric and esophageal cancers and Epcoritamab for blood cancers such as diffuse large B-cell lymphoma. Genmab employs proprietary technologies like DuoBody and HexaBody, which aim to address both solid tumors and hematological malignancies. Through strategic collaborations with industry leaders such as Seagen, argenx, and AbbVie, Genmab enhances its research and development efforts. Established in 1999, the company remains committed to advancing oncology treatment and improving patient outcomes through its innovative therapeutic solutions.



© 2026 WMDST — The World’s Most Dangerous Swing Trader. All rights reserved.